PRMEPrime Medicine, Inc.

$771M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$51M

Net Income

-$51M

EPS (Diluted)

$-0.55

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$42M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$239M

Total Liabilities

$45M

Stockholders' Equity

$194M

Cash & Equivalents

$44M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$51M	-$32M	-62.6%
Net Income	-$51M	-$36M	-42.0%

PRME Q3 2023 Earnings — Prime Medicine, Inc. Revenue & Financial Results | Market Cap Arena